GlassScriptPhysician profile
Taylor Jay Stichter
NPI 1194310052
$2,026.34
in general payments reported to CMS, 2019-2025
27 companies · $487 in 2025
The $487 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $50.63 · 2023: $620 · 2024: $868 · 2025: $487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,976.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,975.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $334.32 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $243.66 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Dexcom, INC. | $242.15 | 2023-2025 | Dexcom G6 Transmitter |
| Impulse Dynamics (USA) INC. | $151.86 | 2025 | Optimizer |
| Amgen INC. | $128.11 | 2023-2024 | Tepezza, Repatha |
| Tandem Diabetes Care, INC. | $110.65 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Novartis Pharmaceuticals Corporation | $89.04 | 2024-2025 | |
| Medtronic, INC. | $85.09 | 2023-2025 | Minimed 780g |
| Bayer Healthcare Pharmaceuticals INC. | $68.19 | 2023-2024 | |
| Esperion Therapeutics, INC. | $54.30 | 2024 | Nexletol |
| Organon LLC | $50.63 | 2022 | |
| Ascendis Pharma Endocrinology INC | $47.12 | 2025 | Yorvipath |
| Alexion Pharmaceuticals, INC. | $43.82 | 2023-2025 | Strensiq |
| Horizon Therapeutics Plc | $43.28 | 2023 | Tepezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.36 | 2023-2024 | Jardiance |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $36.73 | 2023-2025 | |
| Abbvie INC. | $33.28 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $33.10 | 2023 | Steglatro, Januvia |
| Insulet Corporation | $29.44 | 2023 | Omnipod |
| Corcept Therapeutics | $23.85 | 2025 | Korlym |
| Neurocrine Biosciences, INC. | $21.57 | 2025 | |
| Averitas Pharma INC. | $21.47 | 2024 | Qutenza |
| Ascensia Diabetes Care US INC. | $21.15 | 2024 | |
| Xeris Pharmaceuticals, INC. | $19.95 | 2025 | Gvoke Hypopen |
| Recordati_rare_diseases_inc. | $18.25 | 2025 | Isturisa |
| Pfizer INC. | $17.75 | 2024 | |
| Ibsa Pharma INC. | $17.22 | 2023 | Tirosint, Licart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Stichter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.